VCYT FY 2023 Earnings — Veracyte, Inc. Revenue & Financial Results | Market Cap Arena

VCYTVeracyte, Inc.

$3B

FY 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$361M+21.8% YoY

Gross Profit

$248M68.7% margin

Operating Income

-$86M-23.8% margin

Net Income

-$74M-20.6% margin

EPS (Diluted)

$-1.02

Cash Flow

Operating Cash Flow

$44M

Free Cash Flow

$34M

Stock-Based Comp.

$33M

Balance Sheet

Total Assets

$1.1B

Total Liabilities

$71M

Stockholders' Equity

$1.0B

Cash & Equivalents

$216M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$361M	$297M	+21.8%
Gross Profit	$248M	$195M	+27.3%
Operating Income	-$86M	-$41M	-108.8%
Net Income	-$74M	-$37M	-103.5%